Advances in dialysis encephalopathy research: a review.
Ying ChenXin TianXuefeng WangPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2018)
Dialysis encephalopathy (DE) is a progressive, fatal disease with a high mortality rate. Understanding the causes of this disease and the efforts to prevent and treat it would help improve the prognosis and quality of life of affected patients. This paper reviews the etiology, clinical features, methods of examining accessory features, diagnosis, treatment, and prevention of DE. We found that DE is likely to be related to aluminum poisoning. The clinical manifestations of DE include language disorders, mental and behavioral disorders, cognitive decline, and movement disorders. Electroencephalogram (EEG) findings mainly consist of an abundance of low waves, intermittent bilateral synchronous high-amplitude spikes, and ridge waves. Assessing the clinical features and obtaining an EEG are of great value in diagnosis, and DE is treated by both reducing aluminum intake and increasing aluminum excretion. Deferoxamine (DFO) is an effective treatment for DE.
Keyphrases
- end stage renal disease
- cognitive decline
- chronic kidney disease
- peritoneal dialysis
- resting state
- newly diagnosed
- mild cognitive impairment
- functional connectivity
- early onset
- working memory
- multiple sclerosis
- autism spectrum disorder
- cardiovascular events
- cardiovascular disease
- ejection fraction
- mental health
- systematic review
- risk factors
- high intensity
- case report
- coronary artery disease
- oxide nanoparticles
- wastewater treatment